Molecular pathogenesis of childhood acute lymphoblastic leukemia. 1998

A Biondi, and G Masera
Clinica Pediatrica, Università di Milano, Italy.

This concise review focuses on the most recent advances in understanding molecular genetic abnormalities in childhood acute leukemia (ALL). An increasing number of chromosomal translocations associated to distinct molecular genetic abnormalities have been described. Recurrent motifs have been recognized behind the great heterogeneity of genes involved in chromosomal translocations occurring in childhood ALL. The expression or activation of specific genes encoding for transcription factors have been recognized to be the most frequent recurring mechanism. In addition to the identification of genes involved in translocations, the analysis of deleted or mutated genes has provided new insights into the molecular pathogenesis of childhood ALL. The understanding of the genetic heterogeneity has turned out to have great impact on routine diagnosis and treatment. Molecular analysis has revealed that the t(12;21) translocation, barely detectable when searched for by conventional cytogenetic techniques, is the most frequent genetic lesion occurring in childhood ALL. Accumulating evidence clearly indicates that molecular characterisation at diagnosis represents the most relevant prognostic information for risk stratification of the patients at diagnosis. Several target genes are now available for the study of minimal residual disease and to evaluate its potential impact for tailoring treatment. Finally, our progress in understanding the relationships between genetic lesions and environmental etiologic agents will further contribute to delineating the natural history of pediatric ALL.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma

Related Publications

A Biondi, and G Masera
October 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Biondi, and G Masera
June 1998, Leukemia research,
A Biondi, and G Masera
June 2002, Reviews in clinical and experimental hematology,
A Biondi, and G Masera
January 1997, The oncologist,
A Biondi, and G Masera
March 1988, Pediatric annals,
A Biondi, and G Masera
July 1979, Minnesota medicine,
A Biondi, and G Masera
December 1987, Hematology/oncology clinics of North America,
A Biondi, and G Masera
October 1984, American family physician,
A Biondi, and G Masera
January 2000, Journal of biological regulators and homeostatic agents,
A Biondi, and G Masera
December 2023, Cancer innovation,
Copied contents to your clipboard!